# Unifuzol® in Patients With Peripheral Arterial Disease

Study · id `cardio:ct-nct03861416` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03861416](<https://clinicaltrials.gov/study/NCT03861416>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03861416

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

## Technical summary

Registry record NCT03861416. Randomized; double masking; primary purpose treatment. Start 2018-03-16 (actual); primary completion 2019-09-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 360 participants (enrolled count; ClinicalTrials.gov record NCT03861416, source copy `cardio:ctgov-nct03861416-2020-01-31`, retrieved 2026-10-31)
- Started: 2018-03-16 (actual) (ClinicalTrials.gov record NCT03861416, source copy `cardio:ctgov-nct03861416-2020-01-31`, retrieved 2026-10-31)
- Primary completion: 2019-09-13 (actual) (ClinicalTrials.gov record NCT03861416, source copy `cardio:ctgov-nct03861416-2020-01-31`, retrieved 2026-10-31)
- Completion: 2019-10-26 (actual) (ClinicalTrials.gov record NCT03861416, source copy `cardio:ctgov-nct03861416-2020-01-31`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT03861416, source copy `cardio:ctgov-nct03861416-2020-01-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03861416-2020-01-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: "Unifuzol®" in Patients With Peripheral Arterial Disease
- Condition: Peripheral Arterial Disease
- Intervention (Drug): L-arginine 1.4% 500 ml
- Intervention (Drug): L-arginine 1.4% 250 ml + placebo 250 ml
- Intervention (Drug): Placebo solution
- Lead sponsor: POLYSAN Scientific & Technological Pharmaceutical Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 98b154916b48c57845937b28b888f6267adb3969d0d1da683d6f774e1826df68
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
